Press release from Companies
Published: 2019-06-17 16:08:57
Prospectus relating to the rights issue in Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) has been approved and registered by the Danish Financial Supervisory Authority and is now available at Scandion Oncology’s website (www.scandiononcology.com), Sedermera Fondkommission (www.sedermera.se) and at the website of Spotlight Stock Market (www.spotlightstockmarket.com). Teaser and subscription form will be published on the webpages mentioned above at the start of the subscription period. The prospectus has also been passported to Sweden.
Motivation for the rights issue To increase the commercial potential of the drug candidate SCO-101, Scandion Oncology’s new strategy is to run two clinical Phase II studies in metastatic, drug-resistant cancer patients. By initiating two Phase II clinical studies in parallel, i.e. colorectal and breast cancer, and with two different types of chemotherapy the Company will mitigate the risk by pursuing different cancer indications and increase the commercial value for SCO-101. Increased subscription commitments Scandion Oncology has prior to the planned rights issue in writing agreed on subscription commitments and “top-down” guarantee commitments. The subscription commitments have increased by SEK 2 million from previously communicated SEK 16.9 million to SEK 18.9 million. Thus, Scandion Oncology has through subscription commitments and guarantee commitments agreed on approximately SEK 26.1 million corresponding to approximately 89 % of the issue volume. Investor meetings In connection with the rights issue, Scandion Oncology will present the business and future plans at a number of investor events. See schedule below for details. Participation at the investor events is free of charge. Summary of the offering Summary of the consideration free warrants Financial advisor, issuing agent and legal advisor Sedermera Fondkommission is the financial advisor and issuing agent of Scandion Oncology in connection with the rights issue. Markets & Corporate Law acts as the legal advisor. For additional information regarding the rights issue, please contact: Sedermera Fondkommission Phone: +46 (0) 40-615 14 10 E-mail: info@sedermera.se For more information regarding Scandion Oncology, please contact: Nils Brünner, CEO Phone: +45 26 14 47 08 E-mail: nb@scandiononcology.com www.scandiononcology.com This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 17th, 2019. Scandion Oncology is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, was found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. In addition SCO-101 restores chemotherapy sensitivity in in vitro grown resistant cancer cells. Scandion Oncology will in Q4 2019 initiate a clinical phase II study with SCO-101 in combination with chemotherapy. Scandion Oncology was listed on Spotlight, Sweden in November 2018.
Date and time
Event
Place
Registration
June 24, 201917:30 – 19:30
Investor meeting in Stockholm
Scandic AnglaisHumlegårdsgatan 23102 44 Stockholm
Registration is made at www.sedermera.se
June 25, 201917:30 – 19.30
Investor meeting in Copenhagen
Copenhagen Admiral Hotel Toldbodgade 24-281253 Copenhagen
Registration is made at www.sedermera.se
June 26, 201911:30 – 13.00
Investor meeting in Malmo
Malmö BörshusSkeppsbron 2211 20 Malmo
Registration is made at www.sedermera.se
June 27, 201911:30 – 13.00
Investor meeting in Gothenburg
Elite Park Avenue HotelKungsportsavenyen 36411 36 Gothenburg
Registration is made at www.sedermera.se